Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Tatiana Segura
University of California Los Angeles, Department: Surgery
Should you be removed from our database? Contact us at [email protected]. Read more below.
Tempo Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Segura is a co-investigator and is a founder and adviser for the company.
Cell and Gene Replacement Strategies for Arginase Deficiency
Project Narrative This project will be directed at the continuing development of gene and cell replacement strategies for arginase deficiency. Neonatal gene therapy has particular challenges related to rapid hepatocyte proliferation and this proposal will continue to examine gene and cell therapy in that context with application to how such strategies can cure other similar diseases that afflict newborns.
Filed on April 26, 2017.
Tell us what you know about Tatiana Segura's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Tatiana Segura”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Tatiana Segura | Duke University | Conflict of Interest | Tempo Therapeutics, Inc. | $0 - $4,999 |
| Tatiana Segura | Duke University | Conflict of Interest | Tempo Therapeutics, Inc. | Value cannot be readily determined |
| Tatiana Segura | University of California Los Angeles | Conflict of Interest | Tempo Therapeutics, Inc. | $0 - $4,999 |
| Tatiana Segura | University of California Los Angeles | Conflict of Interest | Tempo Therapeutics, Inc. | Value cannot be readily determined |
| Tatiana Segura | University of California Los Angeles | Conflict of Interest | Tempo Therapeutics | Value cannot be readily determined |
| Tatiana Segura | University of California Los Angeles | Conflict of Interest | Tempo Therapeutics | Value cannot be readily determined |
| Tatiana Segura | University of California Los Angeles | Conflict of Interest | Tempo Therapeutics | $0 - $4,999 |
| Tatiana Segura | University of California Los Angeles | Conflict of Interest | Tempo Therapeutics | $0 - $4,999 |
| Tatiana Segura | University of California Los Angeles | Conflict of Interest | Tempo Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.